DiaMedica Therapeutics
DMAC
43 hedge funds and large institutions have $16.9M invested in DiaMedica Therapeutics in 2021 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 14 increasing their positions, 11 reducing their positions, and 6 closing their positions.
33% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 6
27% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 11
5% more funds holding
Funds holding: 41 → 43 (+2)
10.18% less ownership
Funds ownership: 30.32% → 20.14% (-10%)
68% less capital invested
Capital invested by funds: $52.1M → $16.9M (-$35.2M)
88% less call options, than puts
Call options by funds: $63K | Put options by funds: $534K
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JAMONY
Jacob Asset Management of New York
Hermosa Beach,
California
|
+$738K |
| 2 |
Marshall Wace
London,
United Kingdom
|
+$653K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$387K |
| 4 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$314K |
| 5 |
TSS
Two Sigma Securities
New York
|
+$250K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CA
Corriente Advisors
Fort Worth,
Texas
|
-$5.47M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$5.05M |
| 3 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$4.95M |
| 4 |
GPCM
Granite Point Capital Management
Boston,
Massachusetts
|
-$1.69M |
| 5 |
EI
EAM Investors
Solana Beach,
California
|
-$990K |
DMAC Hedge Fund Activity: Q2 2021 in Review
43 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in DiaMedica Therapeutics (DMAC) for Q2 2021, worth a combined $16.9M — down 68% from $52.1M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new DMAC positions and 6 closed out — a net gain of 2 holders — while 14 added to existing stakes and 11 trimmed.
The largest buyer was Jacob Asset Management of New York, adding an estimated $738K. The largest seller was Corriente Advisors, cutting an estimated $5.47M.
- 43 institutional investors held DiaMedica Therapeutics (DMAC) as of Q2 2021, up from 41 in Q1 2021.
- Funds reported $16.9M of DiaMedica Therapeutics stock for Q2 2021, down 68% quarter-over-quarter.
- 8 funds opened new DiaMedica Therapeutics positions in Q2 2021 and 6 closed out, a net change of +2 holders.
- The largest DiaMedica Therapeutics buyer in Q2 2021 was Jacob Asset Management of New York, an estimated $738K added.
- The largest DiaMedica Therapeutics seller in Q2 2021 was Corriente Advisors, an estimated $5.47M sold.
Based on aggregated 13F filings for Q2 2021.